Imaging Biomarkers to Distinguish CBD from Other Tauopathies
Overview of brain imaging biomarkers to identify Corticobasal Degeneration (CBD) subjects and their use in clinical trials of disease-modifying therapeutics.
Imaging Biomarkers for Progressive Supranuclear Palsy (PSP)
An overview of the various brain imaging methods (MRI, PET, SPECT) available to assess efficacy of disease-modifying therapeutics in clinical trials of PSP.
Longitudinal Change in Tau PET in MCI & Alzheimer’s Disease
An overview of the natural history of change in Tau PET tracer uptake & binding in Mild Cognitive Impairment (MCI) & Alzheimer’s disease (AD).
MRI in Clinical Trials of Multiple System Atrophy (MSA)
This resource provides an overview of the utility of volumetric MRI and diffusion-weighted imaging (DWI) as biomarkers in research studies of MSA.
